Regulation of p53R2 and its role as potential target for cancer therapy

Clofarabine Has Apoptotic Effect on T47D Breast Cancer Cell Line via P53R2 Gene Expression

“…homodimers including hRRM1 (R1) and hRRM2 (R2). 6,7 P53, R1 and R2 are expressed in a cell cycle dependent manner. R1 and R2 expressed completely during the S-phase.…”

“…14 Because of the long half-life, R1 level is constant higher than R2 level throughout cell cycle. 6,15 In early G1-phase, R2, but not P53R2, is degraded by cadherin 1/anaphase promoting complex (Cdh1/APC). 12 Thus, in G1phase, P53R2 acts with R1 instead of R2 to provide dNTPs for DNA.…”

“…12 The maximum level of P53R2 has been found at G1/S transition. 6 Furthermore, P53R2 up-regulates P21 and down-regulates cyclin D, 15 causing cell cycle arrest in G1 and providing both time and dNTP for the repair of damaged DNA. Also, P53R2 plays an important role in mitochondrial veracity.…”

Molecular analysis and functions of p53R2 in zebrafish

“…It is shown that the level of p53R2 is closely associated with drug sensitivity and tumor invasiveness. For instance, inhibition of p53R2 increased the sensitivity of cancer cells to DNA-damaging reagents, suggesting that it is a potential target for anticancer drugs (Wang et al, 2009). X-ray structure of human p53R2 has been clarified for the development of specific inhibitor to p53R2 (Smith et al, 2009).…”

Optimization and evaluation of electroporation delivery of siRNA in the human leukemic CEM cell line

“…The R1 protein is expressed constantly and predominantly in proliferating cells, while the smaller R2 protein is cell cycle regulated (Nordlund and Reichard 2006). Another protein called p53-induced R2 protein (p53R2) has been shown to form an active RR complex with the R1 subunit in G1-or non-proliferating cells (Guittet et al 2001;Wang et al 2009). Nucleoside analog resistance can sometimes be explained by increased expression of one or several of these subunits leading to increased endogenous dNTPs competing with the active nucleoside analogs for the same place of incorporation (Bergman et al 2005;Goan et al 1999;Mansson et al 2003).…”